Ligand validation:1R1L

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 1R1L designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
1R1L_NAG_I_941	32%	76%	0.203	0.878	0.38	0.57	-	-	7	0	100%	1
1R1L_NAG_I_901	17%	71%	0.252	0.835	0.42	0.69	-	-	4	1	100%	1
1R1L_NAG_L_841	8%	71%	0.283	0.755	0.44	0.67	-	-	7	1	100%	1
1R1L_NAG_I_961	3%	69%	0.315	0.64	0.52	0.67	-	-	6	0	100%	1
1R1L_NAG_L_801	2%	73%	0.388	0.697	0.51	0.53	-	-	1	0	100%	1
1R1L_NAG_I_962	1%	75%	0.437	0.641	0.4	0.56	-	-	1	1	100%	1
1R1L_NAG_I_942	0%	73%	0.513	0.54	0.5	0.55	-	-	3	1	100%	1
2B4X_NAG_L_841	44%	56%	0.167	0.894	0.68	0.99	-	2	4	0	100%	0.9333
4EB1_NAG_I_801	37%	68%	0.179	0.878	0.57	0.66	-	-	0	0	100%	0.9333
1LK6_NAG_I_841	36%	74%	0.205	0.9	0.44	0.58	-	-	8	0	100%	1
2B5T_NAG_I_801	33%	68%	0.209	0.889	0.56	0.66	-	-	0	0	100%	0.9333
3EVJ_NAG_L_801	28%	63%	0.222	0.875	0.55	0.86	-	-	0	0	100%	0.9333
3H0C_NAG_A_794	100%	56%	0.021	0.995	0.61	1.08	-	1	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3GXM_NAG_A_498	100%	45%	0.026	0.992	0.75	1.34	-	2	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.